Liaoning Chengda Biotechnology Co. Ltd. Class ASSE: 688739

Announcement on Obtaining Notice of Approval for Drug Clinical Trials for Influenza Virus Split Vaccine (High Dose)

· Issued by Liaoning Chengda Biotechnology Co. Ltd. Class A via Shanghai Stock Exchange
Announcement on Obtaining Notice of Approval for Drug Clinical Trials for Influenza Virus Split Vaccine (High Dose)

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment